Sharemaestro company-news research for Myriad Genetics Inc (MYGN), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Measured evidence
Company news sentiment
MYGN news sentiment
Myriad Genetics Inc
Company headlines compared by relevance, subject, source independence, tone and the market's completed price response.
Weighted tone49Neutral is 50
Balanced news tone
52/100 evidence confidence
100% direct company focus
2 current stories across 2 publishers
Current company news
Price moving ahead of tone
Balanced news tone is drawn from 2 fresh independent stories, including 2 company-specific items across 2 publishers.
Latest source headline 3 Healthcare Stocks with Open Questions finance.yahoo.com · 12 Aug 2026 02:53What supports the read
2 current stories are mapped specifically to MYGN.
Cross-story agreement is 73/100, indicating a comparatively coherent tape.
What tempers the read
Only 2 publishers currently contribute to the measured read.
Price is moving more forcefully than the current news tone suggests.
49/100
Weighted toneBalanced news tone
52/100
Evidence confidencebuilding confidence
100%/100
Company focus2 direct stories
73/100
Evidence agreement27/100 dispersion
News history
Tone and story flow over 21 days
24 Jul03 Aug13 Aug
Weighted toneStory volumeNeutral 50
Evidence confidence
What supports the score
Confidence rises through sample depth, independent publishers, direct company relevance, freshness and agreement. A high or low tone score is not itself evidence of reliability.
Sample depth25
1.99 effective storiesSource breadth40
2 independent publishersDirect relevance100
company-specific evidence shareFreshness64
recency-weighted evidenceAgreement73
cross-story consistencySource independence50
lower publisher concentrationPrice context
Sentiment against the 26-week price path
Price is moving more forcefully than the current news tone suggests.
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
Value support
News subjects
What is shaping the score
Regulatory and legal201 stories · 50%
Earnings731 stories · 50%
Source mix
Where the evidence comes from
globenewswire.com201 stories · 50%
finance.yahoo.com731 stories · 50%
Recurring subjects
Subjects appearing most often
Earnings2Regulation1Healthcare1Free Cash Flow1Earnings Per Share1Drop1Class Action1Brandon Walker1Bragar Eagel & Squire1Bes1
Earlier readings
How the score has changed
ConstructiveBalanced or withheldCautious
Source headlines
The news behind the score
Every row shows the public evidence used to understand the read. Direct company stories carry more weight than industry or sector context; duplicate coverage is consolidated before scoring.
#173Tone
finance.yahoo.comDirect company coverage
3 Healthcare Stocks with Open Questions
3 Healthcare Stocks with Open Questions Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 22.3% gain over the past six months, beating the S&P 500 by 11.2 percentage points. Regardless of these results, investors must exercise caution as many businesses in this space are subject to heavy regulation that can influence their earnings potential. With that said, here are three healthcare stocks we're steering clear of.
EarningsEarnings Per ShareFree Cash FlowHealthcareRegulation
- Published
- 12 Aug 2026 02:53
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#220Tone
globenewswire.comDirect company coverage
MYRIAD INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Myriad Genetics, Inc. on Behalf of Myriad Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Myriad (MYGN) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Myriad and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at investigations@bespc.com or by telephone at (212) 355-4648. Click here to participate in the action. NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is invest
BesBragar Eagel & SquireBrandon WalkerClass ActionDropEarnings
- Published
- 07 Aug 2026 18:54
- Catalyst
- Regulatory and legal
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
How the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean a balanced tape or that direction has been withheld for insufficient evidence; the status label distinguishes them.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
The page describes completed evidence available at the stated time. It is research context, not a forecast, recommendation, target or execution instruction.